Ophthotech Corporation
Committed to discovering and developing novel therapeutics and gene therapy solutions to treat ophthalmic diseases, with a focus on orphan and age-related retinal diseases
Age-related macular degeneration (AMD) is a serious public health issue that significantly impacts patients' quality of life and the economy. We are a biopharmaceutical company specializing in developing innovative solutions for treating AMD, and we have achieved notable success in this area. Our most advanced product, Fovista®, has demonstrated statistically significant advantages over anti-VEGF monotherapy, resulting in a 62% improvement in vision compared to baseline measurements. We are committed to advancing treatment options for AMD to enhance patient outcomes and reduce the burden of this disease on healthcare systems.
Our specialists
Scientific Advisory Board
David Cheresh, Ph.D.
Dr. Cheresh has more than 200 publications to his credit and his research is widely published, with seven papers cited more than 1,000 times each.Rakesh K. Jain, Ph.D.
Dr. Jain has the rare distinction of being a member of all three of the U.S. National Academies: the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.Learn more
Management Team
Evelyn Harrison, M.B.A.
Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.Kourous A. Rezaei, M.D.
Dr. Rezaei is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a senior partner at Illinois Retina Associates in Chicago.Learn more
AMD Facts & Figures
- 1.25 million people suffer from wet AMD in the United States 1
- 200,000 new cases of wet AMD are diagnosed each year in the United States 2
- $255 billion estimated annual cost of visual impairment due to AMD to health care systems worldwide 2